SCHEMBL278550

SCHEMBL278550

C=CCNc1cc[nH]c(=O)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
RAB9A P51151 4/20 0.41
KDM4E B2RXH2 2/20 0.41
HCAR3 P49019 1/20 0.41
SLC2A1 P11166 1/20 0.37
CDC7 O00311 1/20 0.35
ROCK2 O75116 1/20 0.35
PIM1 P11309 1/20 0.35
PRKACA P17612 1/20 0.35
CDK2 P24941 1/20 0.35
GSK3B P49841 1/20 0.35
HIPK2 Q9H2X6 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
KMT2A Q03164 4/20 0.35
LMNA P02545 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triphosphate SCHEMBL8438673 0.85 HCAR3 (0.35) ALDH1A1RAB9AKDM4EHCAR3SLC2A1
SCHEMBL10865972 0.79 ADORA2A (0.30) ALDH1A1
SCHEMBL4973928 0.77 HCAR3 (0.40) ALDH1A1RAB9AKDM4EHCAR3SLC2A1
SCHEMBL4306636 0.76 DYRK1A (0.31)
SCHEMBL236001 0.76 ALDH1A1 (0.33) ALDH1A1
SCHEMBL65489 0.76 CACNA1C (0.42) ALDH1A1HCAR3CA1CA2CA9
SCHEMBL19692262 0.76 ALDH1A1 (0.33) ALDH1A1
SCHEMBL17372301 0.76 ALDH1A1 (0.33) ALDH1A1
SCHEMBL3680113 0.73 POLB (0.41) ALDH1A1RAB9AKDM4ECDC7ROCK2
SCHEMBL3798154 0.73 ALDH1A1 (0.32) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116987495-A Construction and application of protein membrane macromolecular probe for biological detection 江南大学 2023-11-03 CN claimed
WO-2023114963-A1 COMPOSITIONS AND METHODS FOR SELECTIVELY LABELING SECONDARY AMINES EMORY UNIVERSITY (US) 2023-06-22 WO claimed
CN-114807328-A Method for marking and identifying single-base resolution DNA 浙江大学 2022-07-29 CN claimed
CN-112301118-B Method and kit for simultaneously obtaining RNA abundance and active RNA polymerase sites in full transcriptome range 浙江大学 2022-05-13 CN claimed
US-20020160969-A1 Nucleosides and oligonucleotides containing boron clusters DEPARTMENT OF VETERANS AFFAIRS 2002-10-31 US claimed
EP-1113020-A2 Nucleosides and oligonucleotides containing boron clusters EMORY UNIVERSITY (US) 2001-07-04 EP claimed
US-6180766-B1 OLIGONUCLEOTIDE WITH UNCHARGED INTERNUCLEOTIDE LINKAGE(S) OF 3',5'-O,O-((CARBORAN-1-YL-METHYL)PHOSPHONATE); MADE BY REACTING O-METHYL(O-CARBORAN-1-YL)METHYL PHOSPHONATE WITH PROTECTED NUCLEOSIDE; USE IN BORON NEUTRON CAPTURE THERAPY DEPARTMENT OF VETERANS AFFAIRS 2001-01-30 US claimed
EP-0731808-A4 NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS UNIV EMORY (US) 1997-04-02 EP claimed
EP-0731808-A1 NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS EMORY UNIVERSITY (US) 1996-09-18 EP claimed
WO-1995015333-A1 NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS EMORY UNIVERSITY (US) 1995-06-08 WO claimed
EP-4720339-A1 METHODS FOR DOUBLE-STRANDED SEQUENCING BY SYNTHESIS Illumina, Inc. (US) 2026-04-08 EP disclosed
US-20240401129-A1 METHODS FOR DOUBLE-STRANDED SEQUENCING BY SYNTHESIS ILLUMINA, INC. (US) 2024-12-05 US disclosed
WO-2024249591-A1 METHODS FOR DOUBLE-STRANDED SEQUENCING BY SYNTHESIS ILLUMINA, INC. (US) 2024-12-05 WO disclosed
EP-4457364-A1 METHODS OF NUCLEIC ACID SEQUENCING USING SURFACE-BOUND PRIMERS Illumina, Inc. (US) 2024-11-06 EP disclosed
US-20240229036-A9 NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN KNC LABORATORIES CO., LTD. (JP) 2024-07-11 US disclosed
US-20010044529-A1 Thermolabile phosphorus protecting groups, associated intermediates and methods of use GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2001-11-22 US disclosed
WO-2000056749-A1 N-ACYLPHOSPHORAMIDITES AND THEIR USE IN OLIGONUCLEOTIDE SYNTHESIS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-09-28 WO disclosed
EP-0421777-B1 Further antiviral pyrimidine nucleosides UNIV BIRMINGHAM (GB) 1996-02-28 EP disclosed
WO-1991004982-A1 FURTHER ANTIVIRAL PYRIMIDINE NUCLEOSIDES UNIVERSITY OF BIRMINGHAM (GB) 1991-04-18 WO disclosed
EP-0421777-A1 Further antiviral pyrimidine nucleosides THE UNIVERSITY OF BIRMINGHAM (GB) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020160969-A1 Nucleosides and oligonucleotides containing boron clusters NUDT1, NTPCR, NAMPT ALDH1A1 4697/4885RAB9A 3256/4885KDM4E 4815/4885
US-20010044529-A1 Thermolabile phosphorus protecting groups, associated intermediates and methods of use POLR2H, POLL, POLR1A ALDH1A1 1410/4885RAB9A 3726/4885KDM4E 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.